

21 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/guangzhou-lupengnewave-pharmaceutical-inc-enrolled-the-first-patient-in-the-global-phase-3-rocket-cll-trial-evaluating-rocbrutinib-lp-168-vs-pirtobrutinib-in-rr-cllsll-302779014.html